Catherine Sazdanoff - 29 Dec 2021 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Reporting relationship: Director
Issuer ticker: INM
Reported as of: 29 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Dec 2021, 17:03:21 UTC
Next SEC filing: 28 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Bruce Colwill, attorney-in-fact for Mrs. Catherine Sazdanoff

Key filing fact

Catherine Sazdanoff filed Form 4 for InMed Pharmaceuticals Inc. (INM) on 30 Dec 2021.

Key facts

This page summarizes Catherine Sazdanoff's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Dec 2021, 17:03.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INM transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +7,000
Change %: +32%
Price: $0.000000
Shares after: 29,091
Date: 29 Dec 2021
Ownership: Direct
Underlying class: Common shares
Underlying amount: 7,000
Exercise price: $1.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner.